Stocks Health care PTHS
NYSE · Health carePelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. brought in $43.3M of revenue over the twelve months to June 30, 2026. It posted a net loss of $86.4M. In fiscal 2025 capital spending exceeded operating cash flow by $22.7M. At June 30, 2026 it held $24.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Pelthos Therapeutics Inc.
- Net worth
- Pelthos Therapeutics Inc. has a market value (market cap) of $35.9M at the latest share price, and shareholders' equity of -$1.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $16.8M, with a net loss of $43.3M. Over the 12 months to June 30, 2026: revenue $43.3M, net loss $86.4M.
- Cash flow
- In fiscal 2025 operations used $22.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Pelthos Therapeutics Inc. does
Pelthos Therapeutics Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker PTHS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $16.8M | -$43.3M | -$23.04 | -$22.7M |
| 2024 | $0 | -$8M | -$14.27 | -$5.8M |
| 2023 | n/a | -$7.4M | -$57.68 | n/a |
| 2023 | n/a | -$2.5M | $56.38 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PTHS ranks in Health care
Latest SEC filings
What Pelthos Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 1, 2026Executive or director change8-KPelthos Therapeutics stockholders approved the 2026 Equity Incentive Plan, elected eight directors, and ratified the company independent auditor at the annual meeting.
- August 18, 2026
- August 18, 2026Additional proxy material DEFA14A
- August 18, 2026Proxy statement DEF 14A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue was $15.6M; diluted EPS -$6.62 versus -$5.29.
- August 13, 2026
- August 13, 2026Quarterly report (amended) 10-Q/A · period to March 31, 2026Revenue was $10.9M; diluted EPS -$7.57 versus -$3.21.
- August 13, 2026
- August 7, 2026Preliminary proxy statement PRE 14A
- May 28, 2026
Insider trades
What the people running Pelthos Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $44.9K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 2, 2026 | Pauls MatthewDirector | Soldpre-planned (10b5-1) | 786 | $16.5K |
| October 2, 2026 | Friedberg Ezra MDirector | Soldpre-planned (10b5-1) | 558 | $11.6K |
| October 2, 2026 | Greenleaf PeterDirector | Soldpre-planned (10b5-1) | 797 | $16.9K |
| July 2, 2026 | Greenleaf PeterDirector | Soldpre-planned (10b5-1) | 712 | $18.5K |
| July 2, 2026 | Greenleaf PeterDirector | Soldpre-planned (10b5-1) | 85 | $2.3K |
| July 2, 2026 | Pauls MatthewDirector | Soldpre-planned (10b5-1) | 692 | $18K |
| July 2, 2026 | Pauls MatthewDirector | Soldpre-planned (10b5-1) | 94 | $2.6K |
| July 2, 2026 | Friedberg Ezra MDirector | Soldpre-planned (10b5-1) | 534 | $13.9K |
Who owns PTHS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| 3i, LP13G, passive with 2 related filers | 9.9% | May 7, 2026 |
| Alexandra Wood (Canada) Inc.13G, passive | 9.53% | January 15, 2025 |
| Murchinson Ltd.13G, passive with 1 related filers | 9.1% | November 14, 2025 |
| Ezra Friedberg13D, may seek influence with 2 related filers | 8.3% | July 3, 2025 |
| Ikarian Capital, LLC13G, passive with 1 related filers | 7.7% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 24 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| AIGH Capital Management LLC | 329,098 | new |
| Murchinson Ltd. | 304,302 | +7,988 |
| Ikarian Capital, LLC | 256,598 | 0 |
| Boothbay Fund Management, LLC | 101,976 | +20,118 |
| Vanguard Capital Management LLC | 97,134 | +4,041 |
| Cantor Fitzgerald, L. P. | 76,246 | +34,823 |
| J. Goldman & Co LP | 38,075 | -12,340 |
| Diadema Partners LP | 24,773 | 0 |
| Wexford Capital LP | 22,364 | new |
| Knott David M Jr | 22,073 | +1,000 |
| Citadel Advisors LLC | 15,046 | new |
| Geode Capital Management, LLC | 14,650 | -640 |
| Pale Fire Capital SE | 12,919 | 0 |
| 1492 Capital Management LLC | 10,380 | new |
| Vanguard Fiduciary Trust Co | 9,873 | +56 |
| State Street Corp | 9,800 | new |
| Persistent Asset Partners Ltd | 6,007 | 0 |
| BlackRock, Inc. | 5,324 | new |
| UBS Group AG | 2,217 | +1,453 |
| China Universal Asset Management Co., Ltd. | 2,160 | new |
Insiders
10 insiders reported holding 426,550 shares in total, about $3.8M at the last price.
| Holder | Shares |
|---|---|
| Friedberg Ezra MDirector | 110,48430,000 held indirectly |
| Plesha Scott M.CEO and President, Director | 83,678 |
| Davis Todd CDirector | 75,834 |
| Francis Knuettel IICFO, Treas & Secty | 30,84111,316 held indirectly |
| Rangarao SaiChief Commercial Officer | 30,518 |
| Malamut RichardDirector | 27,422 |
| Greenleaf PeterDirector | 23,087 |
| Baxter Richard BDirector | 19,108 |
| Pauls MatthewDirector | 13,578 |
| Einhorn Andrew J.Director | 12,000 |
Questions about PTHS
What does Pelthos Therapeutics Inc. do?
Pelthos Therapeutics Inc. is a company in the Health care sector, listed on NYSE as PTHS. Its shares trade on NYSE under the ticker PTHS.
What is Pelthos Therapeutics Inc.'s net worth?
Pelthos Therapeutics Inc. has a market value (market cap) of $35.9M at the latest share price, and shareholders' equity of -$1.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Pelthos Therapeutics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $86.4M on revenue of $43.3M.
How much revenue does Pelthos Therapeutics Inc. make?
Over the twelve months to June 30, 2026 Pelthos Therapeutics Inc. reported revenue of $43.3M.
When did Pelthos Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 6, 2026.
Similar companies
Compare PTHS with
Follow PTHS
Get an email when Pelthos Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Pelthos Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.